EDP Sciences logo
Authentification abonné
rechercher
Menu
Accueil Tous les numéros Volume 207 / Numéro 4 (2013) Biologie Aujourd'hui, 207 4 (2013) 231-240 Références
Accès gratuit
Numéro
Biologie Aujourd'hui
Volume 207, Numéro 4, 2013
Page(s) 231 - 240
DOI https://doi.org/10.1051/jbio/2013027
Publié en ligne 5 mars 2014
  • Bienaimé F., Dragon-Durey M.A., Régnier C.H., Nilsson S.C., Kwan W.H., Blouin J., Jablonski M., Renault N., Rameix-Welti M.A., Loirat C., Sautes-Fridman C., Villoutreix B.O., Blom A.M., Frémeaux-Bacchi V., Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int, 2010, 77, 339–349. [CrossRef] [PubMed] [Google Scholar]
  • Blanc C., Roumenina L.T., Ashraf Y., Hyvarinen S., Sethi S.K., Ranchin B., Niaudet P., Loirat C., Gulati A., Bagga A., Fridman W.H., Sautes-Fridman C., Jokiranta T.S., Frémeaux-Bacchi V., Dragon-Durey M.A., Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J Immunol, 2012, 189, 3528–3537. [CrossRef] [PubMed] [Google Scholar]
  • Bresin E., Rurali E., Caprioli J., Sanchez-Corral P., Frémeaux-Bacchi V., Rodriguez de Cordoba S., Pinto S., Goodship T.H., Alberti M., Ribes D., Valoti E., Remuzzi G., Noris M., Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol, 2013, 24, 475–486. [CrossRef] [PubMed] [Google Scholar]
  • Cornec-Le Gall E., Delmas Y., de Parscau L., Doucet L., Ogier H., Benoist J.F., Frémeaux-Bacchi V., Le Meur Y., Adult-Onset Eculizumab-Resistant Hemolytic Uremic Syndrome Associated With Cobalamin C Deficiency. Am J Kidney Dis, 2014, 63, 119–123. [CrossRef] [PubMed] [Google Scholar]
  • Delvaeye M., Noris M., De Vriese A., Esmon C.T., Esmon N.L., Ferrell G., Del-Favero J., Plaisance S., Claes B., Lambrechts D., Zoja C., Remuzzi G., Conway E.M., Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med, 2009, 361, 345–357. [CrossRef] [PubMed] [Google Scholar]
  • Dragon-Durey M.A., Loirat C., Cloarec S., Macher M.A., Blouin J., Nivet H., Weiss L., Fridman W.H., Frémeaux-Bacchi V., Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol, 2005, 16, 555–563. [CrossRef] [PubMed] [Google Scholar]
  • Eremina V., Jefferson J.A., Kowalewska J., Hochster H., Haas M., Weisstuch J., Richardson C., Kopp J.B., Kabir M.G., Backx P.H., Gerber H.P., Ferrara N., Barisoni L., Alpers C.E., Quaggin S.E., VEGF inhibition and renal thrombotic microangiopathy, N Engl J Med, 2008, 358, 1129–1136. [CrossRef] [PubMed] [Google Scholar]
  • Ermini L., Goodship T.H., Strain L., Weale M.E., Sacks S.H., Cordell H.J., Frémeaux-Bacchi V., Sheerin N.S., Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Mol Immunol, 2011, 49, 640–648. [CrossRef] [PubMed] [Google Scholar]
  • Frémeaux-Bacchi V., Dragon-Durey M.A., Blouin J., Vigneau C., Kuypers D., Boudailliez B., Loirat C., Rondeau E., Fridman W.H., Complement factor I : a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet, 2004, 41, e84. [CrossRef] [PubMed] [Google Scholar]
  • Frémeaux-Bacchi V., Miller E.C., Liszewski M.K., Strain L., Blouin J., Brown A.L., Moghal N., Kaplan B.S., Weiss R.A., Lhotta K., Kapur G., Mattoo T., Nivet, Wong W., Gie S., Hurault de Ligny B., Fischbach M., Gupta R., Hauhart R., Meunier V.H., Loirat C., Dragon-Durey M.A., Fridman W.H., Janssen B.J., Goodship T.H., Atkinson J.P., Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood, 2008, 112, 4948–4952. [CrossRef] [PubMed] [Google Scholar]
  • Frémeaux-Bacchi V., Fakhouri F., Garnier A., Bienaimé F., Dragon-Durey M.A., Ngo S., Moulin B., Servais A., Provot F., Rostaing L., Burtey S., Niaudet P., Deschênes G., Lebranchu Y., Zuber J., C. Loirat., Genetics and outcome of atypical hemolytic uremic syndrome : a nationwide French series comparing children and adults. Clin J Am Soc Nephrol, 2013, 8, 554−562. [CrossRef] [PubMed] [Google Scholar]
  • Frimat M., Tabarin F., Dimitrov J.D., Poitou C., Halbwachs-Mecarelli L., Frémeaux-Bacchi V., Roumenina L.T., Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood, 2013, 122, 282–292. [CrossRef] [PubMed] [Google Scholar]
  • Goicoechea de Jorge E., Harris C.L., Esparza-Gordillo J., Carreras L., Arranz E.A., Garrido C.A., Lopez-Trascasa M., Sanchez-Corral P., Morgan B.P., Rodriguez de Cordoba S., Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA, 2007, 104, 240–245. [CrossRef] [Google Scholar]
  • Le Quintrec M., Zuber J., Moulin B., Kamar N., Jablonski M., Lionet A., Chatelet V., Mousson C., Mourad G., Bridoux F., Cassuto E., Loirat C., Rondeau E., Delahousse M., Frémeaux-Bacchi V., Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant, 2013, 13, 663–675. [CrossRef] [PubMed] [Google Scholar]
  • Legendre C.M., Licht C., Muus P., Greenbaum L.A., Babu S., Bedrosian C., Bingham C., Cohen D.J., Delmas Y., Douglas K., Eitner F., Feldkamp T., Fouque D., Furman R.R., Gaber O., Herthelius M., Hourmant M., Karpman D., Lebranchu Y., Mariat C., Menne J., Moulin B., Nurnberger J., Ogawa M., Remuzzi G., Richard T., Sberro-Soussan R., Severino B., Sheerin N.S., Trivelli A., Zimmerhackl L.B., Goodship T., Loirat C., Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med, 2013, 368, 2169–2181. [CrossRef] [PubMed] [Google Scholar]
  • Lemaire M., Frémeaux-Bacchi V., Schaefer F., Choi M., Tang W.H., Le Quintrec M., Fakhouri F., Taque S., Nobili F., Martinez F., Ji W., Overton J.D., Mane S.M., Nurnberg G., Altmuller J., Thiele H., Morin D., Deschênes G., Baudouin V., Llanas B., Collard L., Majid M.A., Simkova E., Nurnberg P., Rioux-Leclerc N., Moeckel G.W., Gubler M.C., Hwa J., Loirat C., Lifton R.P., Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet, 2013, 45, 531–536. [CrossRef] [PubMed] [Google Scholar]
  • Loirat C., Frémeaux-Bacchi V., Atypical hemolytic uremic syndrome. Orphanet J Rare Dis, 2012, 6, 60. [CrossRef] [Google Scholar]
  • Menne J., Nitschke M., Stingele R., Abu-Tair M., Beneke J., Bramstedt J., Bremer J.P., Brunkhorst R., Busch V., Dengler R., Deuschl G., Fellermann K., Fickenscher H., Gerigk C., Goettsche A., Greeve J., Hafer C., Hagenmuller F., Haller H., Herget-Rosenthal S., Hertenstein B., Hofmann C., Lang M., Kielstein J.T., Klostermeier U.C., Knobloch J., Kuehbacher M., Kunzendorf U., Lehnert H., Manns M.P., Menne T.F., Meyer T.N., Michael C., Munte T., Neumann-Grutzeck C., Nuernberger, Pavenstaedt H., Ramazan L., Renders L., Repenthin J., Ries W., Rohr A., Rump L.C., Samuelsson O., Sayk F., Schmidt B.M., Schnatter S., Schocklmann H., Schreiber S., von Seydewitz C.U., Steinhoff J., Stracke S., Suerbaum S., van de Loo A., Vischedyk M., Weissenborn K., Wellhoner P., Wiesner M., Zeissig S., Buning J., Schiffer M., Kuehbacher T., Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104 :H4 induced haemolytic uraemic syndrome : case-control study. BMJ, 2012, 345, e4565. [CrossRef] [PubMed] [Google Scholar]
  • Morigi M., Galbusera M., Gastoldi S., Locatelli M., Buelli S., Pezzotta A., Pagani C., Noris M., Gobbi M., Stravalaci M., Rottoli D., Tedesco F., Remuzzi G., Zoja C., Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol, 2011, 187, 172–180. [CrossRef] [PubMed] [Google Scholar]
  • Noris M., Remuzzi G., Atypical hemolytic-uremic syndrome. N Engl J Med, 2009, 361, 1676–1687. [CrossRef] [PubMed] [Google Scholar]
  • Noris M., Brioschi S., Caprioli J., Todeschini M., Bresin E., Porrati F., Gamba S., Remuzzi G., Familial haemolytic uraemic syndrome and an MCP mutation. Lancet, 2003, 362, 1542–1547. [CrossRef] [PubMed] [Google Scholar]
  • Noris M., Caprioli J., Bresin E., Mossali C., Pianetti G., Gamba S., Daina E., Fenili C., Castelletti F., Sorosina A., Piras R., Donadelli R., Maranta R., van der Meer I., Conway E.M., Zipfel P.F., Goodship T.H., Remuzzi G., Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol, 2010, 5, 1844–1859. [CrossRef] [PubMed] [Google Scholar]
  • Ozaltin F., Li B., Rauhauser A., An S.W., Soylemezoglu O., Gonul I.I., Taskiran E.Z., Ibsirlioglu T., Korkmaz E., Bilginer Y., Duzova A., Ozen S., Topaloglu R., Besbas N., Ashraf S., Du Y., Liang C., Chen P., Lu D., Vadnagara K., Arbuckle S., Lewis D., Wakeland B., Quigg R.J., Ransom R.F., Wakeland E.K., Topham M.K., Bazan N.G., Mohan C., Hildebrandt F., Bakkaloglu A., Huang C.L., Attanasio M., DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol, 2013, 24, 377–384. [CrossRef] [PubMed] [Google Scholar]
  • Pickering M.C., Cook H.T., Warren J., Bygrave A.E., Moss J., Walport M.J., Botto M., Uncontrolled C3 activation causes membrano-proliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet, 2002, 31, 424–428. [PubMed] [Google Scholar]
  • Pickering M.C., de Jorge E.G., Martinez-Barricarte R., Recalde S., Garcia-Layana A., Rose K.L., Moss J., Walport M.J., Cook H.T., de Cordoba S.R., Botto M., Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med, 2007, 204, 1249–1256. [CrossRef] [PubMed] [Google Scholar]
  • Richards A., Kemp E.J., Liszewski M.K., Goodship J.A., Lampe A.K., Decorte R., Muslumanoglu M.H., Kavukcu S., Filler G., Pirson Y., Wen L.S., Atkinson J.P., Goodship T.H., Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA, 2003, 100, 12966–12971. [CrossRef] [Google Scholar]
  • Roumenina L.T., Loirat C., Dragon-Durey M.A., Halbwachs-Mecarelli L., Sautes-Fridman C., Frémeaux-Bacchi V., Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods, 2011, 365, 8–26. [CrossRef] [PubMed] [Google Scholar]
  • Roumenina L.T., Frimat M., Miller E.C., Provot F., Dragon-Durey M.A., Bordereau P., Bigot S., Hue C., Satchell S.C., Mathieson P.W., Mousson C., Noël C., Sautes-Fridman C., Halbwachs-Mecarelli L., Atkinson J.P., Lionet A., Frémeaux-Bacchi V., A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood, 2012, 119, 4182–4191. [CrossRef] [PubMed] [Google Scholar]
  • Sharma A.P., Greenberg C.R., Prasad A.N., Prasad C., Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder. Pediatr Nephrol, 2007, 22, 2097–2103. [CrossRef] [PubMed] [Google Scholar]
  • Tarr P.I., Gordon C.A., Chandler W.L., Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet, 2005, 365, 1073–1086. [PubMed] [Google Scholar]
  • Trachtman H., Austin C., Lewinski M., Stahl R.A., Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol, 2012, 8, 658–669. [CrossRef] [PubMed] [Google Scholar]
  • Walport M.J., Complement. First of two parts. N Engl J Med, 2001a, 344, 1058–1066. [CrossRef] [PubMed] [Google Scholar]
  • Walport M.J., Complement. Second of two parts. N Engl J Med, 2001b, 344, 1140–1144. [CrossRef] [PubMed] [Google Scholar]
  • Warwicker P., Goodship T.H., Donne R.L., Pirson Y., Nicholls A., Ward R.M., Turnpenny P., Goodship J.A., Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int, 1998, 53, 836–844. [CrossRef] [PubMed] [Google Scholar]
  • Zoja C., Locatelli M., Pagani C., Corna D., Zanchi C., Isermann B., Remuzzi G., Conway E.M., Noris M., Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice. J Immunol, 2012, 189, 3661–3668. [CrossRef] [PubMed] [Google Scholar]
  • Zuber J., Fakhouri F., Roumenina L.T., Loirat C., Frémeaux-Bacchi V., Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol, 2012, 8, 643–657. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.